The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats

The advent of proprotein convertase subtilisin/kexin type 9 (PCSK9) –inhibiting drugs have provided an effective, but extremely expensive treatment for the management of low density lipoprotein (LDL). Our aim w...

Source: Clinical and Translational Medicine - February 13, 2020 Category: Internal Medicine Authors: Xinyang Li, Meiniang Wang, Xinhua Zhang, Chuxin Liu, Haitao Xiang, Mi Huang, Yingying Ma, Xiaoyan Gao, Lin Jiang, Xiaopan Liu, Bo Li, Yong Hou, Xiuqing Zhang, Shuang Yang and Naibo Yang Tags: Research Source Type: research